SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs enters into agreement for manufacture, supply of selected pharmaceutical formulations

24 Dec 2024 Evaluate

Akums Drugs & Pharmaceuticals has entered into an agreement with one of Leading Global Pharma Company for manufacture and supply of selected pharmaceutical formulations in European Market. Akums group will manufacture and supply multiple SKUs of Oral Liquid Formulation to be marketed in multiple European countries by the Company.

This is in line with Akums growth objective of expanding in European and other regulated markets. The commercial supply of these products from Akums will commence in 2027 till 2032. Akums group will also initiate European approvals of its oral liquid site which it intends to leverage to manufacture these products. The approval of the site and the product dossiers is expected to be received by 2026. Akums already has 2 of its sites (Injectable and Oral Solids) approved by European Regulators. The composite value of the agreement is around Rs 1,760 crore.

Akums group, against this agreement, will receive an upfront payment for product development and site approval from European authorities. The project has been secured with an upfront payment of Rs 880 crore. 

Akums Drugs & Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.

Akums Drugs & Pharma Share Price

535.10 1.00 (0.19%)
22-Apr-2026 10:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1653.60
Dr. Reddys Lab 1214.95
Cipla 1228.85
Zydus Lifesciences 927.30
Lupin 2306.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×